USA-based biotech Locus Biosciences is to receive $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administrat 25 January 2024
Outlining its goal of five launches over five years to 2028, Vertex Pharmaceuticals chief executive Reshma Kewalramani has presented a corporate update at the J 10 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.